)
Edge6 Feb 2026
SharkNinja: Viral by Design
How SharkNinja built a repeatable growth engine, turning overlooked appliance categories into global brands through consumer insight and iteration.
Nxera Pharma
Nxera Pharma (4565) investor relations material
Nxera Pharma Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary13 Feb, 2026
Executive summary
FY 2025 revenue rose to JPY 29.6 billion, driven by strong sales of PIVLAZ and QUVIVIQ, but net loss widened to JPY 12.53 billion due to higher R&D, restructuring, and one-time financial charges.
Core operating loss was JPY 352 million; IFRS operating loss was JPY 8.4 billion, impacted by increased R&D and restructuring costs.
Major restructuring included a 15% workforce reduction, smaller executive team, and strategic refocus on high-value programs.
Expanded pipeline and partnerships, including vamorolone in-licensing and new agreements with Viatris, Holling Bio-Pharma, and Santhera.
Advanced multiple clinical programs, including new Phase 2 and 3 assets with partners like Neurocrine, Centessa, Lilly, and AbbVie.
Financial highlights
Total revenue grew 2.7% year-over-year to JPY 29,615 million, with product sales at JPY 17.8 billion, PIVLAZ at JPY 13.5 billion (+6.8%), and QUVIVIQ at JPY 4.3 billion (+224%).
Core operating loss was JPY 352 million; IFRS operating loss JPY 8.4 billion; net loss JPY 12.53 billion; EPS: -¥138.80.
R&D expenses rose to JPY 14,466 million (+JPY 2,650 million YoY); SG&A expenses decreased by JPY 790 million YoY.
One-off costs included JPY 4.6 billion for convertible bond restructuring and JPY 1.8 billion for restructuring.
Cash and cash equivalents at year-end: JPY 20,365 million (down from JPY 32,268 million prior year).
Outlook and guidance
FY 2026 revenue forecast: JPY 33,800–48,800 million; core operating profit: JPY 7,800–22,800 million; operating profit: JPY 700–15,700 million.
Net product sales guidance: JPY 19.5 billion (PIVLAZ + QUVIVIQ); PIVLAZ expected at JPY 13,800–14,200 million, QUVIVIQ at JPY 5,000–6,000 million.
Assumes JPY 12,500 million in milestone income and JPY 3,500 million reduction in R&D and SG&A costs.
Targeting full-year profitability on an IFRS basis and over 10% cost reduction.
Multiple milestone payments and out-licensing of phase II-ready assets could drive upside.
What drives the FY2026 profit turnaround?
Impact of R&D program prioritization on pipeline?
Cash strategy after bond, vamorolone deals?
Detail cost reduction strategy for FY26 profitability
Quviviq supply chain optimization plan details
NXE'149/NXE'744 licensing strategy update
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Nxera Pharma earnings date
Q1 20261 May, 2026
Nxera Pharma
Next Nxera Pharma earnings date
Q1 20261 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Sosei Group Corporation, also known as Sosei Heptares, is a biopharmaceutical company that specializes in the development of drugs using its proprietary G protein-coupled receptor (GPCR) targeted StaR technology and structure-based drug discovery (SBDD) platform. The company's product lineup includes medicines such as Ultibro, Seebri, Enerzair, Breezhaler, Pivlaz, and Oravi. Sosei Group Corporation is headquartered in Chiyoda-ku, Tokyo, Japan, and its shares are listed on the Tokyo Stock Exchange.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage